CN109310737B - 治疗代谢疾病的组合物和方法 - Google Patents

治疗代谢疾病的组合物和方法 Download PDF

Info

Publication number
CN109310737B
CN109310737B CN201780033504.5A CN201780033504A CN109310737B CN 109310737 B CN109310737 B CN 109310737B CN 201780033504 A CN201780033504 A CN 201780033504A CN 109310737 B CN109310737 B CN 109310737B
Authority
CN
China
Prior art keywords
polypeptide
cmyr
serum
subject
ntcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780033504.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109310737A (zh
Inventor
刘宏利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hep Pharmaceutical Co ltd
Original Assignee
Shanghai Hep Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hep Pharmaceutical Co ltd filed Critical Shanghai Hep Pharmaceutical Co ltd
Publication of CN109310737A publication Critical patent/CN109310737A/zh
Application granted granted Critical
Publication of CN109310737B publication Critical patent/CN109310737B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201780033504.5A 2016-05-30 2017-05-31 治疗代谢疾病的组合物和方法 Active CN109310737B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016103704424 2016-05-30
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (2)

Publication Number Publication Date
CN109310737A CN109310737A (zh) 2019-02-05
CN109310737B true CN109310737B (zh) 2023-05-05

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780033504.5A Active CN109310737B (zh) 2016-05-30 2017-05-31 治疗代谢疾病的组合物和方法

Country Status (10)

Country Link
US (2) US11633454B2 (enExample)
EP (1) EP3463422B1 (enExample)
JP (1) JP7684788B2 (enExample)
KR (1) KR102627084B1 (enExample)
CN (1) CN109310737B (enExample)
AU (1) AU2017274094B2 (enExample)
CA (1) CA3026140A1 (enExample)
DK (1) DK3463422T3 (enExample)
ES (1) ES2979305T3 (enExample)
WO (1) WO2017206898A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058393A1 (en) * 2020-12-28 2024-02-22 Md Healthcare Inc. Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102241744A (zh) * 2010-05-14 2011-11-16 上海贺普生物科技有限公司 一种病毒感染阻断剂、其药物组合物及其应用
CN102675430A (zh) * 2005-08-12 2012-09-19 上海贺普生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
CN104781274A (zh) * 2012-11-12 2015-07-15 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
WO2016055534A2 (en) * 2014-10-07 2016-04-14 Myr Gmbh Combination therapy of hbv and hdv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130316B (zh) 2005-08-12 2017-04-19 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675430A (zh) * 2005-08-12 2012-09-19 上海贺普生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744A (zh) * 2010-05-14 2011-11-16 上海贺普生物科技有限公司 一种病毒感染阻断剂、其药物组合物及其应用
CN104781274A (zh) * 2012-11-12 2015-07-15 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
WO2016055534A2 (en) * 2014-10-07 2016-04-14 Myr Gmbh Combination therapy of hbv and hdv infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bile acid signaling in lipid metabolism: Metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice;Qi et al.;《Biochimica et Biophysica Acta》;20140428;第19-29页 *
Hepatitis B Virus: The "Metabolovirus" Highjacks Cholesterol and Bile Acid Metabolism;Andres Geier;《HEPATOLOGY》;20140731;第60卷(第5期);第1458-1460页 *
Inhibitors of the sodium taurocholate co-transporting polypeptide (NTCP) to study improved metabolism by prolonged bile acid signalling;JOANNE M DONKERS et al.;《XXIII international bile acid meeting bile acid as signal integrators and metabolic modulators》;20141009;第194卷;摘要 *
胆汁酸受体TGR5 激动剂研究进展;林快乐等;《国际药学研究杂志》;20120831;第39卷(第4期);第273-279页 *

Also Published As

Publication number Publication date
CN109310737A (zh) 2019-02-05
EP3463422A1 (en) 2019-04-10
JP7684788B2 (ja) 2025-05-28
AU2017274094A1 (en) 2019-02-14
US11633454B2 (en) 2023-04-25
ES2979305T3 (es) 2024-09-25
JP2019520341A (ja) 2019-07-18
CA3026140A1 (en) 2017-12-07
EP3463422A4 (en) 2020-02-26
DK3463422T3 (da) 2024-07-22
KR20190015392A (ko) 2019-02-13
US20230414706A1 (en) 2023-12-28
US20200323951A1 (en) 2020-10-15
EP3463422B1 (en) 2024-05-22
AU2017274094B2 (en) 2020-09-10
KR102627084B1 (ko) 2024-01-19
WO2017206898A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
CN111225680B (zh) 非酒精性脂肪性肝病的治疗药物
CN106715466B (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物
JP5485876B2 (ja) 代謝疾患の治療における治療剤としての非アシル化グレリン
CA2895755A1 (en) Functionalized exendin-4 derivatives
TW201609795A (zh) 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
US20210252110A1 (en) Methods and compositions for treating hypoglycemic disorders
AU2021229621B2 (en) Peptides as selective GIP receptor agonists
US20230414706A1 (en) Compositions and methods for treating metabolic diseases
JP2022513176A (ja) オキシントモジュリンペプチド類似体製剤
JP7672677B2 (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
JP2025525365A (ja) 改良されたｇｌｐ－１受容体アゴニストを含む融合タンパク質およびその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant